A new Harvard case study examines why AbbVie works on Neglected Tropical Diseases (NTDs) in alliance with key nonprofits.
new case study by the Harvard Kennedy School of Government examines the emergence of product development partnerships as an important tool to help nonprofit drug research organizations and pharmaceutical companies like AbbVie cooperate to tackle neglected tropical diseases, or NTDs.
“Our support of these efforts is not driven by commercial interests but rather by a recognition that our science and scientists can contribute to the discovery and development of needed medicines,” says Jim Sullivan, vice president, pharmaceutical discovery, AbbVie. “Working with research partners such as the Drugs for Neglected Diseases Initiative, Gates Foundation’s TB Drug Accelerator, Medicines for Malaria Venture and some industry peers, I am confident that we can and will have a positive impact in turning the tide against many of these devastating diseases.”
The case study, written by professor Jane Nelson, director of Harvard Kennedy School's corporate responsibility initiative, outlines examples of institutional and individual leadership within AbbVie, as well as our engagement in product development partnerships and alliances to address NTDs such as Chagas disease, dengue fever, Leishmania, helminth infections and others.
Nelson has authored four books and more than 50 reports, papers, book chapters and articles on the role of business in global health and development.
Read the case study.
Watch this video to learn more about how we help solve the world's most difficult health challenges.
